| Trial ID: | L6605 |
| Source ID: | NCT00457093
|
| Associated Drug: |
Glargine
|
| Title: |
A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: glargine|DRUG: detemir
|
| Outcome Measures: |
Primary: In the time period 2400 to 0600 hours (the Basal Period) when post-meal food is least likely to affect the glucose level, detect the mean percentage pf time the glucose level is between 70-119 mg/dL | Secondary: Establish the mean percentage of time spent in the glucose ranges of 40-70 mg/dL, 120-179 mg/dL, 180-240 mg/dL and >240 mg/dL in the Basal Period and for the entire day, and the average glucose for the entire 24 hour period.
|
| Sponsor/Collaborators: |
Sponsor: Diabetes Care Center | Collaborators: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
35
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-10
|
| Completion Date: |
2007-05
|
| Results First Posted: |
|
| Last Update Posted: |
2010-11-18
|
| Locations: |
Diabetes Care Center, Salinas, California, 93901, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00457093
|
